Citations (98)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Robin Chazot, Elisabeth Botelho-Nevers, Anne Frésard, Nicolas Maillard, Christophe Mariat, Frédéric Lucht & Amandine Gagneux-Brunon. (2017) Diagnostic challenges of kidney diseases in HIV-infected patients. Expert Review of Anti-infective Therapy 15:10, pages 903-915.
Read now
Read now
Nicolas A. Margot, Kathryn M. Kitrinos, Marshall Fordyce, Scott McCallister, Michael D. Miller & Christian Callebaut. (2016) Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clinical Trials 17:2, pages 78-87.
Read now
Read now
Stefano Bonora, Andrea Calcagno, Alice Trentalange & Giovanni Di Perri. (2016) Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. Expert Opinion on Pharmacotherapy 17:3, pages 409-419.
Read now
Read now
Magnus Glindvad Ahlström, Bo Feldt-Rasmussen, Rebecca Legarth, Gitte Kronborg, Court Pedersen, Carsten Schade Larsen, Jan Gerstoft & Niels Obel. (2015) Smoking and renal function in people living with human immunodeficiency virus: a Danish nationwide cohort study. Clinical Epidemiology 7, pages 391-399.
Read now
Read now
F. Touzard Romo, L. M. Smeaton, T. B. Campbell, C. Riviere, R. Mngqibisa, M. Nyirenda, K. Supparatpinyo, N. Kumarasamy, J. G. Hakim & T. P. Flanigan. (2014) Renal and Metabolic Toxicities Following Initiation of HIV-1 Treatment Regimen in a Diverse, Multinational Setting: A Focused Safety Analysis of ACTG PEARLS (A5175). HIV Clinical Trials 15:6, pages 246-260.
Read now
Read now
Sana Waheed & Mohamed G Atta. (2014) Predictors of HIV-associated nephropathy. Expert Review of Anti-infective Therapy 12:5, pages 555-563.
Read now
Read now
José Vicente Fernández-Montero, Eugenia Vispo & Vicente Soriano. (2014) Emerging antiretroviral drugs. Expert Opinion on Pharmacotherapy 15:2, pages 211-219.
Read now
Read now
Magnus G. Rasch, Frederik N. Engsig, Bo Feldt-Rasmussen, Ole Kirk, Gitte Kronborg, Court Pedersen, Jan Gerstoft & Niels Obel. (2012) Renal function and incidence of chronic kidney disease in HIV patients: A Danish cohort study. Scandinavian Journal of Infectious Diseases 44:9, pages 689-696.
Read now
Read now
Maxwell O Akanbi, Kimberly Scarsi, Babafemi Taiwo & Robert L Murphy. (2012) Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection. Expert Opinion on Pharmacotherapy 13:1, pages 65-79.
Read now
Read now
Tanuja N Gengiah, Andrew L Gray, Kogieleum Naidoo & Quarraisha Abdool Karim. (2011) Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opinion on Drug Safety 10:4, pages 559-574.
Read now
Read now
Articles from other publishers (88)
Ronald J. Ellis, María J. Marquine, Marcus Kaul, Jerel Adam Fields & Johannes C. M. Schlachetzki. (2023) Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management. Nature Reviews Neurology 19:11, pages 668-687.
Crossref
Crossref
Shirley X. Jiang, John Duncan & Hin Hin Ko. (2023) Acquired Fanconi Syndrome from Tenofovir Treatment in a Patient with Hepatitis B. Case Reports in Hepatology 2023, pages 1-3.
Crossref
Crossref
Nthabiseng Zilwa, Onalethata Mpejane, Golam Mehboob, Sajan Gill & Thomas Kalinoski. (2023) Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report. Antiviral Therapy 28:3.
Crossref
Crossref
Andinet Gizaw, Wendy C. King, Amanda S. Hinerman, Raymond T. Chung, Mauricio Lisker‐Melman, Marc G. Ghany, Mandana Khalili, Mamta K. Jain, Jacob Graham, Theresa Swift‐Scanlan, David E. Kleiner, Mark Sulkowski, David K. Wong & Richard K. Sterling. (2022)
A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (
HBV)‐HIV
co‐infection with high prevalence of tenofovir‐based antiretroviral therapy use
. HIV Medicine 24:1, pages 55-74.
Crossref
Crossref
Lys Carelle Motue Waffo, Jean Marie Dangwang Dikdim, Guy Bertrand Noumi, Domga, Romuald Teguia Doumbi, Ghizlan Kaichouh, Joseph Marie Sieliechi, Imane Haji, Aicha Guessous & Miloud El Karbane. (2022) Electrochemical production of sulfate radicals for degradation of Tenofovir in aqueous solution. Case Studies in Chemical and Environmental Engineering 6, pages 100235.
Crossref
Crossref
Mercy Jelagat Karoney, Mathew Kirtptonui Koech, Evangeline Wawira Njiru & Willis Dixon Owino Ong’or. (2022) Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya. PLOS ONE 17:9, pages e0273183.
Crossref
Crossref
Ayush Sharma, Prakash Kumar, Siddhartha Dutta, Rimple Jeet Kaur, Jaykaran Charan, Gaurav Chikara, Krishna Murti, Murali Kumarasamy, M. Ramesh, Krishna Pandey, V. Ravichandiran & Sameer Dhingra. (2022) Pathophysiological and Genetic Basis of Tenofovir-Induced Acute Renal Dysfunction: Strategies and Recent Developments for Better Clinical Outcomes. Current Pharmacology Reports 8:6, pages 427-438.
Crossref
Crossref
Lucio Boglione, Ilaria De Benedetto, Valentina Dodaro, Marta Chiecchio, Amedeo De Nicolò, Giovanni Di Perri & Antonio D’Avolio. (2022) Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B. Archives of Virology 167:8, pages 1669-1674.
Crossref
Crossref
E Sinakos, P Panas, N Fragkou, N Antoniadis, G Katsanos, E Tsakni, T Oikonomou, A Notopoulos, G Tsoulfas, I Goulis & E Akriviadis. (2022) Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease. Acta Gastro Enterologica Belgica 85:2, pages 331-337.
Crossref
Crossref
Angsana Phuphuakrat, Ekawat Pasomsub, Wasun Chantratita, Surakameth Mahasirimongkol, Sinee Disthabanchong, Somnuek Sungkanuparph & Sasisopin Kiertiburanakul. (2022) Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate. Journal of the International Association of Providers of AIDS Care (JIAPAC) 21, pages 232595822211347.
Crossref
Crossref
Sonia Romero‐Cordero, Antoni Noguera‐Julian, Francesc Cardellach, Clàudia Fortuny & Constanza Morén. (2021) Mitochondrial changes associated with viral infectious diseases in the paediatric population. Reviews in Medical Virology 31:6.
Crossref
Crossref
Chen‐Hua Liu, Hsin‐Yun Sun, Szu‐Min Hsieh, Wen‐Chun Liu, Wang‐Hui Sheng, Chun‐Jen Liu, Tung‐Hung Su, Tai‐Chung Tseng, Pei‐Jer Chen, Chien‐Ching Hung & Jia‐Horng Kao. (2021) Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus‐coinfected patients receiving sofosbuvir‐based direct‐acting antivirals and antiretroviral therapy. Journal of Viral Hepatitis 28:6, pages 887-896.
Crossref
Crossref
Amedeo De Nicolò, Alessandra Manca, Alice Ianniello, Alice Palermiti, Andrea Calcagno, Micol Ferrara, Miriam Antonucci, Jessica Cusato, Valeria Avataneo, Elisa De Vivo, Stefano Bonora, Francesco Giuseppe De Rosa, Giovanni Di Perri & Antonio D’Avolio. (2021) Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. Pharmaceuticals 14:5, pages 460.
Crossref
Crossref
Tyler Lanman, Scott Letendre, Qing Ma, Anne Bang & Ronald Ellis. (2019) CNS Neurotoxicity of Antiretrovirals. Journal of Neuroimmune Pharmacology 16:1, pages 130-143.
Crossref
Crossref
Joseph P Gaut & Helen Liapis. (2021) Acute kidney injury pathology and pathophysiology: a retrospective review. Clinical Kidney Journal 14:2, pages 526-536.
Crossref
Crossref
Anaïs Brayette, Marie Essig, Paul Carrier, Marilyne Debette-Gratien, Anaïs Labrunie, Sophie Alain, Marianne Maynard, Nathalie Ganne-Carrié, Eric Nguyen-Khac, Pauline Pinet, Victor De Ledinghen, Christophe Renou, Philippe Mathurin, Claire Vanlemmens, Vincent Di Martino, Anne Gervais, Juliette Foucher, Fouchard-Hubert Isabelle, Julien Vergniol, Isabelle Hourmand-Ollivier, Daniel Cohen, Xavier Duval, Thierry Poynard, Marc Bardou, Armand Abergel, Manh-Thong Dao, Thierry Thévenot, Jean-Baptiste Hiriart, Valérie Canva, Guillaume Lassailly, Christine Aurières, Nathalie Boyer, Dominique Thabut, Pierre-Henri Bernard, Matthieu Schnee, Dominique Larrey, Bertrand Hanslik, Séverine Hommel, Jérémie Jacques & Véronique Loustaud-Ratti. (2020) Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus. World Journal of Hepatology 12:12, pages 1326-1340.
Crossref
Crossref
Muzamil O. Hassan, Raquel Duarte, Victor O. Mabayoje, Caroline Dickens, Akeem O. Lasisi & Saraladevi Naicker. (2020) Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study. BMC Nephrology 21:1.
Crossref
Crossref
Hebing Guo, Jingyuan Liu, Lin Pu, Jingjing Hao, Ningning Yin, Yufeng Liu, Haofeng Xiong & Ang Li. (2020) Continuous renal replacement therapy in patients with HIV/AIDS. BMC Nephrology 21:1.
Crossref
Crossref
Eungyeong Jang, Jong Kil Lee, Kyung-Soo Inn, Eun Kyoung Chung, Kyung-Tae Lee & Jang-Hoon Lee. (2020) Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice. Healthcare 8:4, pages 417.
Crossref
Crossref
Ganesh Selvaraj Duraisamy, Dattatry Bhosale, Ivana Lipenská, Ivana Huvarova, Daniel Růžek, Marc P. Windisch & Andrew D. Miller. (2020) Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?. Viruses 12:9, pages 998.
Crossref
Crossref
. (2020) Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatology Research 50:8, pages 892-923.
Crossref
Crossref
Pere Domingo, Ignacio Suarez-Lozano, Félix Gutierrez, Vicente Estrada, Hernando Knobel, Rosario Palacios, Antonio Antela, José-Ramón Blanco & Xavier Fulladosa. (2019) Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. Nefrología (English Edition) 39:5, pages 497-505.
Crossref
Crossref
Pere Domingo, Ignacio Suarez-Lozano, Félix Gutierrez, Vicente Estrada, Hernando Knobel, Rosario Palacios, Antonio Antela, José-Ramón Blanco & Xavier Fulladosa. (2019) Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. Nefrología 39:5, pages 497-505.
Crossref
Crossref
Rong-Yue Liang, Jing-Hang Xu, Chong-Wen Si, Sa Wang, Jia Shang, Zu-Jiang Yu, Qing Mao, Qing Xie, Wei Zhao, Jun Li, Zhi-Liang Gao, Shan-Ming Wu, Hong Tang, Jun Cheng, Xin-Yue Chen, Wen-Hong Zhang, Hao Wang, Zhong-Nan Xu, Ling Wang, Jun Dai & Yan-Yan Yu. (2019) A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B. Medicine 98:33, pages e16778.
Crossref
Crossref
Asim Kichloo, Savneek Singh Chugh, Sanjeev Gupta, Jay Panday & Ghazaleh Goldar. (2019) Tenofovir and Severe Symptomatic Hypophosphatemia. Journal of Investigative Medicine High Impact Case Reports 7, pages 232470961984879.
Crossref
Crossref
JL Casado, C Santiuste, MJ Vivancos, M Monsalvo, A Moreno, MJ Perez-Elías, JM del Rey & S Moreno. (2018) Switching to abacavir versus use of a nucleoside-sparing dual regimen for HIV-infected patients with tenofovir-associated renal toxicity. HIV Medicine 19:8, pages 541-550.
Crossref
Crossref
Tessa K. Novick, Michael J. Choi, Avi Z. Rosenberg, Blaithin A. McMahon, Derek Fine & Mohamed G. Atta. (2017) Tenofovir alafenamide nephrotoxicity in an HIV-positive patient. Medicine 96:36, pages e8046.
Crossref
Crossref
A. J. Zeder, R. Hilge, S. Schrader, J. R. Bogner & U. Seybold. (2016) Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate. Infection 44:5, pages 641-649.
Crossref
Crossref
Kristen L. Bunnell, Sonia Vibhakar, Robert C. Glowacki, Maureen A. Gallagher, Albert M. Osei & Gregory Huhn. (2016) Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:9, pages e148-e153.
Crossref
Crossref
Cristina Gervasoni, Davide Minisci, Paola Meraviglia, Sara Baldelli, Emilio Clementi, Giuliano Rizzardini & Dario Cattaneo. (2016) Determinants of bone diseases in tenofovir-treated HIV patients. AIDS 30:10, pages 1686-1687.
Crossref
Crossref
Johannes P. Mouton, Christine Njuguna, Nicole Kramer, Annemie Stewart, Ushma Mehta, Marc Blockman, Melony Fortuin-De Smidt, Reneé De Waal, Andy G. Parrish, Douglas P.K. Wilson, Ehimario U. Igumbor, Getahun Aynalem, Mukesh Dheda, Gary Maartens & Karen Cohen. (2016) Adverse Drug Reactions Causing Admission to Medical Wards. Medicine 95:19, pages e3437.
Crossref
Crossref
Silvia A Guillemi, Sean H Ling, Julia S Dahlby, Benita Yip, Wendy Zhang, Mark W Hull, Viviane Dias Lima, Robert S Hogg, Ronald Werb, Julio S Montaner & Marianne Harris. (2016) Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function. Journal of the International AIDS Society 19:1, pages 20995.
Crossref
Crossref
Takashi Sekine. 2016. Pediatric Nephrology. Pediatric Nephrology
1655
1691
.
Aung Myint Thu, Kittiyod Poovorawan, Chatporn Kittitrakul, Apichart Nontprasert, Natthida Sriboonvorakul, Weerapong Phumratanaprapin, Pisit Tangkijvanich, Wattana Leowattana & Polrat Wilairatana. (2015) Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand. BMC Pharmacology and Toxicology 16:1.
Crossref
Crossref
Marco Simiele, Chiara Carcieri, Amedeo De Nicolò, Alessandra Ariaudo, Mauro Sciandra, Andrea Calcagno, Stefano Bonora, Giovanni Di Perri & Antonio D’Avolio. (2015) A LC–MS method to quantify tenofovir urinary concentrations in treated patients. Journal of Pharmaceutical and Biomedical Analysis 114, pages 8-11.
Crossref
Crossref
Pedro Rodríguez Quesada, Laura López Esteban, Jimena Ramón García, Rocío Vázquez Sánchez, Teresa Molina García, Gabriel Gaspar Alonso-Vega & Javier Sánchez-Rubio Ferrández. (2015) Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. International Journal of Clinical Pharmacy 37:5, pages 865-872.
Crossref
Crossref
Hyeon Seok Hwang, Cheol Whee Park & Myeong Jun Song. (2015) Tenofovir‐associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection. Hepatology 62:4, pages 1318-1320.
Crossref
Crossref
Giuseppe Coppolino, Mariadelina Simeoni, Chiara Summaria, Maria Concetta Postorino, Laura Rivoli, Alessio Strazzulla, Carlo Torti & Giorgio Fuiano. (2015) The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. Journal of Nephrology 28:4, pages 393-402.
Crossref
Crossref
Minh Patrick Lê, Roland Landman, Sinata Koulla-Shiro, Charlotte Charpentier, Papa-Salif Sow, Mamadou-Baila Diallo, Ndèye Fatou Ngom Gueye, Maguy Ngolle, Vincent Le Moing, Sabrina Eymard-Duvernay, Aïda Benalycherif, Eric Delaporte, Pierre-Marie Girard, Gilles Peytavin, R. Landman, G. Peytavin, C. Charpentier, S. Koulla-Shiro, M. Ngolle, C. Kouanfack, B. Ymele, O. Elad, P. S. Sow, M. B. Diallo, A. Ouattara, A. Thiam, B. Ndiaye, M. B. Koita Fall, C. Essomba, H. Diop, F. Ngom Gueye, A. Sock, S. Legac, E. Simen, M. Maynart, V. Le Moing, S. Eymard-Duvernay, C. Toure Kane, A. Benalycherif, A. Aghokeng, E. Delaporte & P. M. Girard. (2015) Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. Journal of Antimicrobial Chemotherapy 70:5, pages 1517-1521.
Crossref
Crossref
Linda Aurpibul, Tim R. Cressey, Sirintip Sricharoenchai, Orasri Wittawatmongkol, Virat Sirisanthana, Wanatpreeya Phongsamart, Tavitiya Sudjaritruk & Kulkanya Chokephaibulkit. (2015) Efficacy, Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Virologic-Suppressed HIV-infected Children Using Weight-Band Dosing. Pediatric Infectious Disease Journal 34:4, pages 392-397.
Crossref
Crossref
Justin Mandala, Kavita Nanda, Meng Wang, Irith De Baetselier, Jennifer Deese, Johan Lombaard, Fredrick Owino, Mookho Malahleha, Rachel Manongi, Douglas Taylor & Lut Van Damme. (2014) Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacology and Toxicology 15:1.
Crossref
Crossref
Darren M. Moss, Megan Neary & Andrew Owen. (2014) The role of drug transporters in the kidney: lessons from tenofovir. Frontiers in Pharmacology 5.
Crossref
Crossref
Marieke Ezinga, Jack FM Wetzels, Marjolein EW Bosch, André JAM van der Ven & David M Burger. (2013) Long-Term Treatment with Tenofovir: Prevalence of Kidney Tubular Dysfunction and Its Association with Tenofovir Plasma Concentration. Antiviral Therapy 19:8, pages 765-771.
Crossref
Crossref
Rujuta A Bam, Stephen R Yant & Tomas Cihlar. (2013) Tenofovir Alafenamide is Not a Substrate for Renal Organic Anion Transporters (Oats) and Does Not Exhibit Oat-Dependent Cytotoxicity. Antiviral Therapy 19:7, pages 687-692.
Crossref
Crossref
Magnus G. Rasch, Marie Helleberg, Bo Feldt-Rasmussen, Gitte Kronborg, Carsten S. Larsen, Court Pedersen, Gitte Pedersen, Jan Gerstoft & Niels Obel. (2014) Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population. Nephrology Dialysis Transplantation 29:6, pages 1232-1238.
Crossref
Crossref
Hemalatha Ramamoorthy, Premila Abraham & Bina Isaac. (2014) Mitochondrial Dysfunction and Electron Transport Chain Complex Defect in a Rat Model of Tenofovir Disoproxil Fumarate Nephrotoxicity. Journal of Biochemical and Molecular Toxicology 28:6, pages 246-255.
Crossref
Crossref
Guha Mausumee, Simutis Frank, Clark Shawn, Hawthorne Dara, Yue Zhao, Piche Marie Soleil, Thomas P. Sanderson, Graziano Michael & Davies Marc. (2014) Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy. International Journal of Toxicology 33:3, pages 204-218.
Crossref
Crossref
Ole-Petter R. Hamnvik, Carolyn B. Becker, Bruce D. Levy & Joseph Loscalzo. (2014) Wasting Away. New England Journal of Medicine 370:10, pages 959-966.
Crossref
Crossref
Joseph B. Margolick, Lisa P. Jacobson, George J. Schwartz, Alison G. Abraham, Annie T. Darilay, Lawrence A. Kingsley, Mallory D. Witt & Frank J. Palella. (2014) Factors Affecting Glomerular Filtration Rate, as Measured by Iohexol Disappearance, in Men with or at Risk for HIV Infection. PLoS ONE 9:2, pages e86311.
Crossref
Crossref
Sanjiv M. Baxi, Ruth M. Greenblatt, Peter Bacchetti, Rebecca Scherzer, Howard Minkoff, Yong Huang, Kathryn Anastos, Mardge Cohen, Stephen J. Gange, Mary Young, Michael G. Shlipak & Monica Gandhi. (2014) Common clinical conditions – age, low BMI, ritonavir use, mild renal impairment – affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. AIDS 28:1, pages 59-66.
Crossref
Crossref
Adikwu Elias, Ogbuehi Ijeoma, Nkereuwen Jonathan Edikpo, Deo Oputiri & Oru-Bo Precious Geoffrey. (2014) Tenofovir Renal Toxicity: Evaluation of Cohorts and Clinical Studies—Part 2. Pharmacology & Pharmacy 05:01, pages 97-111.
Crossref
Crossref
Hemalatha Ramamoorthy, Premila Abraham & Bina Isaac. (2014) Preclinical efficacy of melatonin in the amelioration of tenofovir nephrotoxicity by the attenuation of oxidative stress, nitrosative stress and inflammation in rats. Journal of Basic and Clinical Physiology and Pharmacology 25:4.
Crossref
Crossref
Waldo H. Belloso, Mariana de Paz Sierra, Matilde Navarro, Marisa L. Sanchez, Ariel G. Perelsztein & Carlos G. Musso. (2014) Impaired Urine Dilution Capability in HIV Stable Patients. International Journal of Nephrology 2014, pages 1-8.
Crossref
Crossref
Takashi Sekine. 2014. Pediatric Nephrology. Pediatric Nephrology
1
42
.
Kirsten M. Stray, Rujuta A. Bam, Gabriel Birkus, Jia Hao, Eve-Irene Lepist, Stephen R. Yant, Adrian S. Ray & Tomas Cihlar. (2013)
Evaluation of the Effect of Cobicistat on the
In Vitro
Renal Transport and Cytotoxicity Potential of Tenofovir
. Antimicrobial Agents and Chemotherapy 57:10, pages 4982-4989.
Crossref
Crossref
Amy E. Blatt & Scott E. Liebman. (2013) Drug Induced Acute Kidney Injury. Hospital Medicine Clinics 2:4, pages e525-e541.
Crossref
Crossref
M. M. Foisy, C. Hughes, C. Hills-Nieminen, A. E. Singh & A. M. Joffe. (2013) Tenofovir-related nephrotoxicity: An ongoing clinical challenge. American Journal of Health-System Pharmacy 70:15, pages 1272-1274.
Crossref
Crossref
Andrew M. Hall. (2012) Update on tenofovir toxicity in the kidney. Pediatric Nephrology 28:7, pages 1011-1023.
Crossref
Crossref
Murli Purswani, Kunjal Patel, Jeffrey B. Kopp, George R. Seage, Miriam C. Chernoff, Rohan Hazra, George K. Siberry, Lynne M. Mofenson, Gwendolyn B. Scott & Russell B. Van Dyke. (2013) Tenofovir Treatment Duration Predicts Proteinuria in a Multiethnic United States Cohort of Children and Adolescents With Perinatal HIV-1 Infection. Pediatric Infectious Disease Journal 32:5, pages 495-500.
Crossref
Crossref
Isabelle Poizot-Martin, Caroline Solas, Julie Allemand, Véronique Obry-Roguet, Vincent Pradel, Sylvie Bregigeon, Olivia Faucher & Bruno Lacarelle. (2013) Renal Impairment in Patients Receiving a Tenofovir-cART Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:4, pages 375-380.
Crossref
Crossref
Takeshi Nishijima, Hirokazu Komatsu, Katsuji Teruya, Junko Tanuma, Kunihisa Tsukada, Hiroyuki Gatanaga, Yoshimi Kikuchi & Shinichi Oka. (2013) Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml. AIDS 27:5, pages 839-842.
Crossref
Crossref
C. Laprise, J.-G. Baril, S. Dufresne & H. Trottier. (2012) Association Between Tenofovir Exposure and Reduced Kidney Function in a Cohort of HIV-Positive Patients: Results From 10 Years of Follow-up. Clinical Infectious Diseases 56:4, pages 567-575.
Crossref
Crossref
Holger Schmid, Malgorzata Tokarska-Schlattner, Birgit Füeßl, Maximilian Röder, Laurence Kay, Stéphane Attia, Stephan R Lederer, Frank D Goebel, Uwe Schlattner & Johannes R Bogner. (2012) Macro Ck2 Accumulation in Tenofovir-Treated HIV Patients is Facilitated by Ck Oligomer Stabilization but is Not Predictive for Pathology. Antiviral Therapy 18:2, pages 193-204.
Crossref
Crossref
Vania Giacomet. (2013) Proteinuria in paediatric patients with human immunodeficiency virus infection. World Journal of Clinical Cases 1:1, pages 13.
Crossref
Crossref
Premila Abraham, Hemalatha Ramamoorthy & Bina Isaac. (2013) Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney. Journal of Biomedical Science 20:1, pages 61.
Crossref
Crossref
Misao Takano, Junko Tanuma, Kunihisa Tsukada, Katsuji Teruya, Yoshimi Kikuchi, Takeshi Nishijima, Hiroyuki Gatanaga, Shinichi Oka, Takuro Shimbo & Hirokazu Komatsu. (2013) Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. Journal of Infection and Chemotherapy 19:5, pages 850-857.
Crossref
Crossref
Ruxandra Calin, Luc Paris, Anne Simon, Gilles Peytavin, Marc Wirden, Luminita Schneider, Marc-Antoine Valantin, Roland Tubiana, Rachid Agher & Christine Katlama. (2012) Dual Raltegravir/Etravirine Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy. Antiviral Therapy 17:8, pages 1601-1604.
Crossref
Crossref
T. Hulgan & M. Gerschenson. (2012) HIV and Mitochondria: More Than Just Drug Toxicity. Journal of Infectious Diseases 205:12, pages 1769-1771.
Crossref
Crossref
Ziba Jalali & Jürgen K. Rockstroh. (2012) Antiviral Drugs and the Treatment of Hepatitis C. Current HIV/AIDS Reports 9:2, pages 132-138.
Crossref
Crossref
Lene Ryom, Amanda Mocroft & Jens Lundgren. (2012) HIV Therapies and the Kidney: Some Good, Some Not So Good?. Current HIV/AIDS Reports 9:2, pages 111-120.
Crossref
Crossref
R. Rosenbrock & A,J. Schmidt. (2012) AidsAids. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 55:4, pages 535-542.
Crossref
Crossref
Jennifer Broom, David Sowden, Merran Williams, Kuong Taing, Karen Morwood & Karen McGill. (2011) Moving from Viral Suppression to Comprehensive Patient-Centered Care. Journal of the International Association of Physicians in AIDS Care 11:2, pages 109-114.
Crossref
Crossref
A. K. Singal & R. J. Fontana. (2012) Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Alimentary Pharmacology & Therapeutics 35:6, pages 674-689.
Crossref
Crossref
Emmanuelle Plaisier, François-Xavier Lescure & Pierre Ronco. (2012) Rein et infection par le virus de l’immunodéficience humaine. La Presse Médicale 41:3, pages 267-275.
Crossref
Crossref
Edgar Turner OvertonPragna PatelKristin MondyTim BushLois ConleyFrank RhameErna Milunka KojicJohn HammerKeith HenryJohn T. Brooks, for the SUN Study Investiga. (2012) Cystatin C and Baseline Renal Function Among HIV-Infected Persons in the SUN Study. AIDS Research and Human Retroviruses 28:2, pages 148-155.
Crossref
Crossref
Sonia Vibhakar, Diana Yu, Romina Kee & Blake Max. (2012) Ethambutol Induced Optic Neuritis Associated with Tenofovir Nephrotoxicity. World Journal of AIDS 02:02, pages 43-47.
Crossref
Crossref
Takeshi Nishijima, Hirohisa Yazaki, Fumihiko Hinoshita, Daisuke Tasato, Kazufusa Hoshimoto, Katsuji Teruya, Hiroyuki Gatanaga, Yoshimi Kikuchi & Shinichi Oka. (2012) Drug-Induced Acute Interstitial Nephritis Mimicking Acute Tubular Necrosis after Initiation of Tenofovir-Containing Antiretroviral Therapy in Patient with HIV-1 Infection. Internal Medicine 51:17, pages 2469-2471.
Crossref
Crossref
Laura Albini, Bruno Mario Cesana, Davide Motta, Emanuele Focà, Daria Gotti, Alessandra Calabresi, Ilaria Izzo, Rita Bellagamba, Rita Fezza, Pasquale Narciso, Laura Sighinolfi, Paolo Maggi, Eugenia Quiros-Roldan, Luigi Manili, Giovanni Guaraldi, Giuseppe Lapadula & Carlo Torti. (2012) A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:1, pages 18-24.
Crossref
Crossref
Derek Yu & Jenny Heathcote. (2011) Tenofovir in the treatment of chronic hepatitis B. Therapy 8:5, pages 527-544.
Crossref
Crossref
John Phair & Frank Palella. (2011) Renal disease in HIV-infected individuals. Current Opinion in HIV and AIDS 6:4, pages 285-289.
Crossref
Crossref
Alessandra Viganò, Giorgio Bedogni, Valeria Manfredini, Vania Giacomet, Chiara Cerini, Francesca di Nello, Francesca Penagini, Cristiana Caprio & Gian Vincenzo Zuccotti. (2011) Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults. Clinical Drug Investigation 31:6, pages 407-415.
Crossref
Crossref
James J Kohler, Seyed H Hosseini, Elgin Green, Allison Abuin, Tomika Ludaway, Rodney Russ, Robert Santoianni & William Lewis. (2011) Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transporters. Laboratory Investigation 91:6, pages 852-858.
Crossref
Crossref
Andrew M. Hall, Bruce M. Hendry, Dorothea Nitsch & John O. Connolly. (2011) Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence. American Journal of Kidney Diseases 57:5, pages 773-780.
Crossref
Crossref
Miwako Honda, Michiyo Ishisaka, Naoki Ishizuka, Satoshi Kimura & Shinichi Oka. (2011) Open-Label Randomized Multicenter Selection Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir-Boosted Atazanavir to Efavirenz with Fixed-Dose Abacavir and Lamivudine. Internal Medicine 50:7, pages 699-705.
Crossref
Crossref
Kevin Peterson, Sabelle Jallow, Sarah L. Rowland-Jones & Thushan I. de Silva. (2011) Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. AIDS Research and Treatment 2011, pages 1-11.
Crossref
Crossref
Beatriz Fernandez-Fernandez, Ana Montoya-Ferrer, Ana B. Sanz, Maria D. Sanchez-Niño, Maria C. Izquierdo, Jonay Poveda, Valeria Sainz-Prestel, Natalia Ortiz-Martin, Alejandro Parra-Rodriguez, Rafael Selgas, Marta Ruiz-Ortega, Jesus Egido & Alberto Ortiz. (2011) Tenofovir Nephrotoxicity: 2011 Update. AIDS Research and Treatment 2011, pages 1-11.
Crossref
Crossref
Alfredo Alberti & Nicola Caporaso. (2011) HBV therapy: Guidelines and open issues. Digestive and Liver Disease 43, pages S57-S63.
Crossref
Crossref
Anna Maisa, Clare Westhorpe, Julian Elliott, Anthony Jaworowski, Anna C Hearps, Anthony M Dart, Jennifer Hoy & Suzanne M Crowe. (2010) Premature onset of cardiovascular disease in HIV-infected individuals: the drugs and the virus. HIV Therapy 4:6, pages 675-692.
Crossref
Crossref